Literature DB >> 21343701

Epigenetic reprogramming as a key contributor to melanocyte malignant transformation.

Fernanda Molognoni1, Adriana T Cruz, Fabiana M Meliso, Alice S Morais, Camila F Souza, Patrícia Xander, Jared M Bischof, Fabrício F Costa, Marcelo B Soares, Gangning Liang, Peter A Jones, Miriam G Jasiulionis.   

Abstract

Melanoma progression requires deregulation of gene expression by currently uncharacterized epigenetic mechanisms. A mouse model based on changes in cell microenvironment was developed by our group to study melanocyte malignant transformation. Melanoma cell lines (4C11- and 4C11+) were obtained as result of 5 sequential anchorage blockades of non-tumorigenic melan-a melanocytes. Melan-a cells submitted to 4 de-adhesion cycles were also established (4C), are non-tumorigenic and represent an intermediary phase of tumor progression. The aim of this work was to identify factors contributing to epigenetic modifications in early and later phases of malignant transformation induced by anchorage impediment. Epigenetic alterations occur early in tumorigenesis; 4C cell line shows changes in global and gene-specific DNA methylation and histone marks. Many histone modifications differ between melan-a, 4C, 4C11- (non-metastatic melanoma cell line) and 4C11+ (metastatic melanoma cell line) which could be associated with changes in gene and microRNA expression. These epigenetic alterations seem to play a key role in malignant transformation since melanocytes treated with 5-Aza-2'-deoxycytidine before each anchorage blockade do not transform. Some epigenetic changes seem to be also responsible for the maintenance of malignant phenotype, since melanoma cell lines (4C11- and 4C11+) treated in vitro with 5-Aza-2'-deoxycytidine or Trichostatin A showed reduction of tumor growth in vivo. Changes in gene expression reflecting cell adaptation to new environment were also observed. We propose a model in which sustained microenvironmental stress in melanocytes results in epigenetic reprogramming. Thus, after adaptation, cells may acquire epigenetic marks that could contribute to the establishment of a malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343701      PMCID: PMC3359486          DOI: 10.4161/epi.6.4.14917

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  58 in total

Review 1.  Linking DNA methylation and histone modification: patterns and paradigms.

Authors:  Howard Cedar; Yehudit Bergman
Journal:  Nat Rev Genet       Date:  2009-05       Impact factor: 53.242

Review 2.  [Global DNA hipomethylation--the meaning in carcinogenesis].

Authors:  Jolanta Guz; Marek Foksiński; Ryszard Oliński
Journal:  Postepy Biochem       Date:  2010

Review 3.  Chd1 remodelers maintain open chromatin and regulate the epigenetics of differentiation.

Authors:  Jenna Persson; Karl Ekwall
Journal:  Exp Cell Res       Date:  2010-03-06       Impact factor: 3.905

Review 4.  Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.

Authors:  Ping Chi; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

5.  Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway.

Authors:  Michael T McCabe; Joanne N Davis; Mark L Day
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

6.  Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.

Authors:  Pieter A van der Velden; Wieke Zuidervaart; Monique H M H Hurks; Sandra Pavey; Bruce R Ksander; Elise Krijgsman; Rune R Frants; Cornelis P Tensen; Rein Willemze; Martine J Jager; Nelleke A Gruis
Journal:  Int J Cancer       Date:  2003-09-10       Impact factor: 7.396

7.  Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin.

Authors:  Bernhard Lehnertz; Yoshihide Ueda; Alwin A H A Derijck; Ulrich Braunschweig; Laura Perez-Burgos; Stefan Kubicek; Taiping Chen; En Li; Thomas Jenuwein; Antoine H F M Peters
Journal:  Curr Biol       Date:  2003-07-15       Impact factor: 10.834

8.  Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.

Authors:  Suhu Liu; Suping Ren; Paul Howell; Oystein Fodstad; Adam I Riker
Journal:  Pigment Cell Melanoma Res       Date:  2007-06-28       Impact factor: 4.693

9.  Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma.

Authors:  Amanda Gonçalves Dos Santos Silva; Herbert Alexander Graves; Amanda Guffei; Tatiana Iervolino Ricca; Renato Arruda Mortara; Miriam Galvonas Jasiulionis; Sabine Mai
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

10.  Chd1 regulates open chromatin and pluripotency of embryonic stem cells.

Authors:  Alexandre Gaspar-Maia; Adi Alajem; Fanny Polesso; Rupa Sridharan; Mike J Mason; Amy Heidersbach; João Ramalho-Santos; Michael T McManus; Kathrin Plath; Eran Meshorer; Miguel Ramalho-Santos
Journal:  Nature       Date:  2009-07-08       Impact factor: 49.962

View more
  17 in total

1.  TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.

Authors:  Elise Bonvin; Enrico Radaelli; Martin Bizet; Flavie Luciani; Emilie Calonne; Pascale Putmans; David Nittner; Nitesh Kumar Singh; Sara Francesca Santagostino; Valérie Petit; Lionel Larue; Jean Christophe Marine; François Fuks
Journal:  Cancer Res       Date:  2018-12-11       Impact factor: 12.701

2.  miRNAs and Melanoma: How Are They Connected?

Authors:  Adriana Taveira da Cruz; Miriam Galvonas Jasiulionis
Journal:  Dermatol Res Pract       Date:  2011-08-10

3.  Biomarkers as key contributors in treating malignant melanoma metastases.

Authors:  Camila Ferreira de Souza; Alice Santana Morais; Miriam Galvonas Jasiulionis
Journal:  Dermatol Res Pract       Date:  2011-10-31

4.  Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients.

Authors:  Debora D'Angelo Papaiz; Flávia Eichemberger Rius; Ana Luísa Pedroso Ayub; Clarice S Origassa; Hemant Gujar; Diogo de Oliveira Pessoa; Eduardo Moraes Reis; Jérémie Nsengimana; Julia Newton-Bishop; Christopher E Mason; Daniel J Weisenberger; Gangning Liang; Miriam Galvonas Jasiulionis
Journal:  Mol Oncol       Date:  2022-02-04       Impact factor: 7.449

5.  Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation.

Authors:  Fernanda Molognoni; Fabiana Henriques Machado de Melo; Camila Tainah da Silva; Miriam Galvonas Jasiulionis
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

6.  Epigenetic modulations in activated cells early after HIV-1 infection and their possible functional consequences.

Authors:  Juliana T Maricato; Maria N Furtado; Maisa C Takenaka; Edsel R M Nunes; Patricia Fincatti; Fabiana M Meliso; Ismael D C G da Silva; Miriam G Jasiulionis; Maria Cecília de Araripe Sucupira; Ricardo Sobhie Diaz; Luiz M R Janini
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patients.

Authors:  Adriana Taveira da Cruz; Aline Hunger; Fabiana Henriques Machado de Melo; Ana Carolina Monteiro; Geneviève Catherine Paré; Dulce Lai; Débora Kristina Alves-Fernandes; Ana Luisa Pedroso Ayub; Esteban Mauricio Cordero; José Franco da Silveira Filho; Regine Schneider-Stock; Bryan Eric Strauss; Victor Tron; Miriam Galvonas Jasiulionis
Journal:  Neoplasia       Date:  2021-07-08       Impact factor: 5.715

8.  Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis.

Authors:  Camila Ferreira de Souza; Patrícia Xander; Ana Carolina Monteiro; Amanda Gonçalves dos Santos Silva; Débora Castanheira Pereira da Silva; Sabine Mai; Viviane Bernardo; José Daniel Lopes; Miriam Galvonas Jasiulionis
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

9.  The Roles of miR-26, miR-29, and miR-203 in the Silencing of the Epigenetic Machinery during Melanocyte Transformation.

Authors:  Cláudia Regina Gasque Schoof; Alberto Izzotti; Miriam Galvonas Jasiulionis; Luciana Dos Reis Vasques
Journal:  Biomed Res Int       Date:  2015-11-04       Impact factor: 3.411

10.  Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFβ1-induced macrophages.

Authors:  Camila Maria Longo Machado; Luciana Nogueira Sousa Andrade; Verônica Rodrigues Teixeira; Fabrício Falconi Costa; Camila Morais Melo; Sofia Nascimento dos Santos; Suely Nonogaki; Fu-Tong Liu; Emerson Soares Bernardes; Anamaria Aranha Camargo; Roger Chammas
Journal:  Cancer Med       Date:  2014-01-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.